{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T23:44:59Z","timestamp":1769903099221,"version":"3.49.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":281,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Departmental Innovation funds at the H. Lee Moffitt Cancer Center & Research Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>AbstractAbstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Specific herpesviruses have been implicated in glioma development. We undertook a pilot study to examine whether herpesviruses-specific human T-cell receptor (TCR) sequences in patient blood samples associate with glioma grade and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was based on 56 pretreatment blood samples collected from both patients with glioblastoma (n\u2009=\u200936) with varying survival times as well as 20 lower grade glioma patients, including astrocytomas and oligodendrogliomas. Following PCR amplification and high-throughput sequencing of DNA extracted from peripheral blood, data were analyzed (AdaptiveBiotechnologies ImmunoSEQ Analyzer) to identify complementarity-determining (CDR3) regions of human TCRs specific to herpes viral antigens. We identified sequences specific for six cytomegalovirus (CMV) peptides and ten Epstein-Barr virus peptides. No CDR3 sequences specific for Varicella Zoster could be identified in the publicly available databases queried.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Blood samples yielded large numbers of productive rearrangements (ie CDR3 sequences resulting in functional T-cell immunity), and one or more sequences targeting CMV and EBV were found in every patient sample. For both EBV and CMV, we observed a greater breadth (higher average number of unique CDR3 sequences) and intensity (higher average sum of all CDR3 sequences) of antiviral T-cell response in patients with lower-grade gliomas compared with glioblastoma, even after adjustment for patient age and sex in multivariate regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Interrogation of blood samples for CDR3 sequences describing the human TCR repertoire offers a novel tool for investigating anti-viral immune response in glioma. More robust immunity to herpesviruses could result in cross-reactive, primed cyto-toxic immune responses that potentially suppress development of more aggressive tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf216","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:46:38Z","timestamp":1759837598000},"source":"Crossref","is-referenced-by-count":0,"title":["T-cell receptor sequencing for detection of Epstein-Barr and cytomegalovirus-specific immune responses in glioma patients: An exploratory study"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-7499","authenticated-orcid":false,"given":"Anna E","family":"Coghill","sequence":"first","affiliation":[{"name":"Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida"},{"name":"Cancer Epidemiology Program, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Van Bibber","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Program, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Yoder","sequence":"additional","affiliation":[{"name":"Molecular Genomics Core, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Mokhtari","sequence":"additional","affiliation":[{"name":"Department of Neurooncology, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sugriva","family":"Forsyth","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Program, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Blanck","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Morsani College of Medicine, University of South Florida , Tampa, Florida"},{"name":"Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M","family":"Egan","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Program, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2026013106570196800_vdaf216-B1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2016.10.022","article-title":"Cytomegalovirus as an oncomodulatory agent in the progression of glioma","volume":"384","author":"Joseph","year":"2017","journal-title":"Cancer Lett"},{"key":"2026013106570196800_vdaf216-B2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/NEN.0000000000000125","article-title":"Cytomegalovirus and glioblastoma: a review of evidence for their association and indications for testing and treatment","volume":"73","author":"Solomon","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"2026013106570196800_vdaf216-B3","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/cam4.682","article-title":"History of chickenpox in glioma risk: a report from the glioma international case-control study (GICC)","volume":"5","author":"Amirian","year":"2016","journal-title":"Cancer Med"},{"key":"2026013106570196800_vdaf216-B4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.ajhg.2022.04.011","article-title":"The immunogenetics of viral antigen response is associated with subtype-specific glioma risk and survival","volume":"109","author":"Guerra","year":"2022","journal-title":"Am J Hum Genet"},{"key":"2026013106570196800_vdaf216-B5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/neuonc\/noac283","article-title":"Antibodies to varicella-zoster virus and three other herpesviruses and survival in adults with glioma","volume":"25","author":"Guerra","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026013106570196800_vdaf216-B6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ijc.33987","article-title":"Prospective investigation of herpesvirus infection and risk of glioma","volume":"151","author":"Coghill","year":"2022","journal-title":"Int J Cancer"},{"key":"2026013106570196800_vdaf216-B7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/13524585241235825","article-title":"EBV infection drives MS pathology: yes","volume":"30","author":"Aloisi","year":"2024","journal-title":"Mult Scler"},{"key":"2026013106570196800_vdaf216-B8","first-page":"325","article-title":"Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage","volume":"95","author":"Jons","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026013106570196800_vdaf216-B9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/vim.2024.0013","article-title":"IGH complementarity determining region-3-Cytomegalovirus protein chemical complementarity linked to better overall survival probabilities for glioblastoma","volume":"37","author":"Hudock","year":"2024","journal-title":"Viral Immunol"},{"key":"2026013106570196800_vdaf216-B10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/PPO.0b013e318238216e","article-title":"Implementing personalized medicine in a cancer center","volume":"17","author":"Fenstermacher","year":"2011","journal-title":"Cancer J"},{"key":"2026013106570196800_vdaf216-B11","doi-asserted-by":"crossref","first-page":"10861","DOI":"10.1038\/s41598-019-47284-4","article-title":"Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma","volume":"9","author":"Creed","year":"2019","journal-title":"Sci Rep"},{"key":"2026013106570196800_vdaf216-B12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jmedgenet-2012-100941","article-title":"Rare TP53 genetic variant associated with glioma risk and outcome","volume":"49","author":"Egan","year":"2012","journal-title":"J Med Genet"},{"key":"2026013106570196800_vdaf216-B13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11060-010-0506-0","article-title":"Cancer susceptibility variants and the risk of adult glioma in a US case-control study","volume":"104","author":"Egan","year":"2011","journal-title":"J Neurooncol"},{"key":"2026013106570196800_vdaf216-B14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mito.2022.01.002","article-title":"Mitochondrial DNA sequence variation and risk of glioma","volume":"63","author":"Samanic","year":"2022","journal-title":"Mitochondrion"},{"key":"2026013106570196800_vdaf216-B15","doi-asserted-by":"crossref","first-page":"D1057","DOI":"10.1093\/nar\/gkz874","article-title":"VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium","volume":"48","author":"Bagaev","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"2026013106570196800_vdaf216-B16","doi-asserted-by":"crossref","first-page":"e2300057","DOI":"10.1200\/PO.23.00057","article-title":"Neuroblastoma and glioblastoma cases with amplified oncogenes have reduced numbers of Tumor-Resident adaptive immune receptor recombinations","volume":"7","author":"Dabkowski","year":"2023","journal-title":"JCO Precis Oncol."},{"key":"2026013106570196800_vdaf216-B17","doi-asserted-by":"crossref","first-page":"e00980","DOI":"10.1128\/JVI.00980-19","article-title":"Epstein-Barr Virus-Specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with Virus-Infected cells: clue for a Virus-Driven immunopathological mechanism","volume":"93","author":"Serafini","year":"2019","journal-title":"J Virol"},{"key":"2026013106570196800_vdaf216-B18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/jnnp-2014-307727","article-title":"Cytomegalovirus and glioma: putting the cart before the horse","volume":"86","author":"Dey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026013106570196800_vdaf216-B19","doi-asserted-by":"crossref","first-page":"e1514921","DOI":"10.1080\/2162402X.2018.1514921","article-title":"The role of CMV in glioblastoma and implications for immunotherapeutic strategies","volume":"8","author":"Rahman","year":"2019","journal-title":"Oncoimmunology"},{"key":"2026013106570196800_vdaf216-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.81178","article-title":"The story of human cytomegalovirus and cancer: increasing evidence and open questions","volume":"11","author":"Michaelis","year":"2009","journal-title":"Neoplasia"},{"key":"2026013106570196800_vdaf216-B21","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s43018-025-00998-z","article-title":"A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial","volume":"6","author":"Thompson","year":"2025","journal-title":"Nat Cancer"},{"key":"2026013106570196800_vdaf216-B22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fonc.2014.00275","article-title":"Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme","volume":"4","author":"Schuessler","year":"2014","journal-title":"Front Oncol"},{"key":"2026013106570196800_vdaf216-B23","doi-asserted-by":"crossref","first-page":"818447","DOI":"10.3389\/fonc.2022.818447","article-title":"The basis and advances in clinical application of Cytomegalovirus-Specific cytotoxic T cell immunotherapy for glioblastoma multiforme","volume":"12","author":"Daei Sorkhabi","year":"2022","journal-title":"Front Oncol"},{"key":"2026013106570196800_vdaf216-B24","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the Central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf216\/64569775\/vdaf216.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf216\/64569775\/vdaf216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf216\/64569775\/vdaf216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:57:11Z","timestamp":1769860631000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf216\/8279652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf216","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf216"}}